Search results for "LER"

showing 10 items of 14795 documents

2021

Mutations in TSC1 or TSC2 genes are linked to alterations in neuronal function which ultimately lead to the development of a complex neurological phenotype. Here we review current research on the effects that reduction in TSC1 or TSC2 can produce on the developing neural network. A crucial feature of the disease pathophysiology appears to be an early deviation from typical neurodevelopment, in the form of structural abnormalities. Epileptic seizures are one of the primary early manifestation of the disease in the CNS, followed by intellectual deficits and autism spectrum disorders (ASD). Research using mouse models suggests that morphological brain alterations might arise from the interacti…

0301 basic medicineDiseaseBiologyCatalysisInorganic Chemistry03 medical and health sciencesTuberous sclerosisEpilepsy0302 clinical medicinemedicinePhysical and Theoretical ChemistryMolecular BiologySpectroscopyOrganic ChemistryGlutamate receptorGeneral Medicinemedicine.diseasePhenotypeComputer Science Applications030104 developmental biologymedicine.anatomical_structureAutismTSC1TSC2Neuroscience030217 neurology & neurosurgeryInternational Journal of Molecular Sciences
researchProduct

Abacavir Induces Arterial Thrombosis in a Murine Model.

2018

Background The purinergic system is known to underlie prothrombotic and proinflammatory vascular programs, making the profile of experimental actions demonstrated by abacavir compatible with thrombogenesis. However, direct evidence of a prothrombotic effect by the drug has been lacking. Methods The present study appraised the effects of abacavir in a well-validated animal model of arterial thrombosis. The role of ATP-P2X7 receptors in the actions of the drug was also assessed, and the actions of recognized vascular-damaging agents and other nucleoside reverse-transcriptase inhibitors (NRTIs) were evaluated and compared to those of abacavir. Results Abacavir dose-dependently promoted thrombu…

0301 basic medicineDrugMaleAnti-HIV Agentsmedia_common.quotation_subject030204 cardiovascular system & hematologyPharmacologyProinflammatory cytokine03 medical and health sciences0302 clinical medicineimmune system diseasesAbacavirmedicineImmunology and AllergyAnimalsRofecoxibmedia_commonMice KnockoutDose-Response Relationship Drugbusiness.industryPurinergic receptorAntagonistvirus diseasesThrombosisPurinergic signallingmedicine.diseaseThrombosisDideoxynucleosidesDisease Models Animal030104 developmental biologyInfectious DiseasesReceptors Purinergic P2X7businessmedicine.drugThe Journal of infectious diseases
researchProduct

Cardiovascular toxicity of abacavir: a clinical controversy in need of a pharmacological explanation.

2017

: There is a long-lasting controversy surrounding an association between abacavir (ABC) and an increased risk of cardiovascular disease in HIV-positive patients. Although differing in their specifics, a number of published cohort studies and clinical trials support such an association, usually relating it to recent exposure to the drug, independently of traditional predisposing factors. However, other clinical trials have failed to reveal such a relation and have pointed to methodological differences to explain discrepancies. Significantly, the controversy has been fueled by the lack of a credible mechanism of action to justify the putative detrimental actions of ABC. There is a myriad of c…

0301 basic medicineDrugVasculitisAnti-HIV Agentsmedia_common.quotation_subjectImmunologyHIV InfectionsDiseasePharmacologyBioinformaticsProinflammatory cytokine03 medical and health sciencesParacrine signallingchemistry.chemical_compound0302 clinical medicineAbacavirImmunology and AllergyMedicineHumans030212 general & internal medicineCyclic guanosine monophosphatemedia_commonbusiness.industryAtherosclerosis030112 virologyDideoxynucleosidesClinical trialInfectious DiseaseschemistryMechanism of actionCardiovascular Diseasesmedicine.symptombusinessmedicine.drugAIDS (London, England)
researchProduct

Autism spectrum disorders in children affected by Duchenne muscular dystrophy

2018

Background Duchenne muscular dystrophy (DMD) is the most frequent and severe form of the dystrophinopathies. The literature shows that about 30-40% of DMD subjects have intellectual disability. In males with Duchenne muscular dystrophy, neuropsychiatric disorders have also been observed: attention deficit disorder and hyperactivity, autism spectrum disorders, and obsessive-compulsive disorder. Duchenne muscular dystrophy is not just a muscle disorder, but also a disease that affects the brain. The aim of the present study was to describe a case series of children with Duchenne muscular dystrophy that have also the presence of autism spectrum disorders (ASDs). They have been assessed by mean…

0301 basic medicineDuchenne muscular dystrophyMalemedicine.medical_specialtyAutism Spectrum DisorderDuchenne muscular dystrophyMuscle disorderAudiologyAutism Diagnostic Observation Schedule03 medical and health sciences0302 clinical medicineIntellectual Disabilitymental disordersIntellectual disabilitymedicineHumansMuscular dystrophyChildbusiness.industryWechsler Adult Intelligence Scalemedicine.diseaseSettore MED/39 - Neuropsichiatria InfantileMuscular Dystrophy Duchenne030104 developmental biologyPediatrics Perinatology and Child HealthChildhood Autism Rating ScaleAutismAustism Spectrum Disorderbusiness030217 neurology & neurosurgeryHuman
researchProduct

EGFL7 - a potential therapeutic target for multiple sclerosis?

2018

0301 basic medicineEGF Family of ProteinsMultiple SclerosisClinical BiochemistryEndothelial Growth FactorsBlood–brain barrier03 medical and health sciences0302 clinical medicineDrug DiscoveryMedicineAnimalsHumansMolecular Targeted TherapyPharmacologybusiness.industryMultiple sclerosisNatalizumabCalcium-Binding Proteinsmedicine.disease030104 developmental biologymedicine.anatomical_structureBlood-Brain BarrierMolecular MedicineEGFL7businessNeuroscience030217 neurology & neurosurgeryExpert opinion on therapeutic targets
researchProduct

MODULATION OF GRO-ALPHA AND TNF-ALPHA PRODUCTION BY PERIPHERAL BLOOD MONONUCLEAR CELLS TREATED WITH KILLED HELICOBACTER PYLORI.

2007

GRO-alpha seems to play an important role in recruiting and activating neutrophils during Helicobacter pylori infection. In the present study, we examined how treatment with killed H. pylori or/and live H. pylori may differentially influence the in vitro GRO-alpha and TNF-alpha release by peripheral blood mononuclear cells (PBMC). The amounts of TNF-alpha and GRO-alpha produced by PBMC after stimulation with live H. pylori were higher than those produced after stimulation with a combination of killed and live H. pylori and the latter were higher than those produced after stimulation with killed H. pylori. In conclusion, the treatment of peripheral blood mononuclear cells with killed H. pyl…

0301 basic medicineEXPRESSIONImmunologyGASTRIC-MUCOSAlcsh:MedicineGASTRIC-MUCOSA; IN-VITRO; CHEMOKINE; GRANULOCYTES; EXPRESSION; INFECTION; SECRETIONGRANULOCYTESPeripheral blood mononuclear cell03 medical and health sciences0302 clinical medicineINFECTIONImmunology and AllergybiologyChemistrylcsh:RIN-VITROHelicobacter pyloribacterial infections and mycosesbiology.organism_classificationMolecular biologyCHEMOKINE030104 developmental biology030220 oncology & carcinogenesisImmunologySECRETIONlipids (amino acids peptides and proteins)
researchProduct

A Pharmacological Update of Ellagic Acid.

2018

Este artículo se encuentra disponible en la página web de la revista en la siguiente URL: https://www.thieme-connect.com/products/ejournals/pdf/10.1055/a-0633-9492.pdf This is a pre-print of an article published in Ríos, JL., Giner, RM., Marín, M. and Recio, MC. (2018). A pharmacological update of ellagic acid. Planta Medica, vol. 84, n. 15, pp. 1068-1093. The final authenticated version is available online at: https://doi.org/10.1055/a-0633-9492 Este es el pre-print del siguiente artículo Ríos, JL., Giner, RM., Marín, M. and Recio, MC. (2018). A pharmacological update of ellagic acid. Planta Medica, vol. 84, n. 15, pp. 1068-1093 que se ha publicado de forma definitiva en https://doi.org/10…

0301 basic medicineEllagic acid - Pharmacokinetics.Antioxidantmedicine.medical_treatmentMetaboliteInterleukin-1betaAnti-Inflammatory AgentsPharmaceutical ScienceApoptosisPharmacologyProtective AgentsProteína quinasa.NeuroprotectionAntioxidantsAnalytical Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEllagic AcidGlycationDrug DiscoverymedicineHumansProtein kinases.Cell ProliferationPharmacologyMetabolic SyndromeAldose reductaseInterleukin-6Tumor Necrosis Factor-alphaMetabolismo - Trastornos.Organic ChemistryNF-kappa BLipid metabolismAtherosclerosisEllagic acid - Physiological effect.NeuroprotectionMetabolism disorder030104 developmental biologyComplementary and alternative medicinechemistryÁcido elágico - Efectos fisiológicos.Antioxidantes.Ácido elágico - Farmacocinética.030220 oncology & carcinogenesisMolecular MedicineMetabolism - Disorders.Antioxidants.Ellagic acidPlanta medica
researchProduct

The emergence of loss of efficacy during antidepressant drug treatment for major depressive disorder: An integrative review of evidence, mechanisms, …

2018

The re-emergence (i.e. ‘breakthrough’) of depressive symptoms despite maintenance treatment of depression with antidepressant drugs is a complex clinical phenomenon referred to as tolerance. Herein we critically appraise evidence from both pre-clinical and clinical studies, focusing on putative mechanisms as well as clinical correlates and implications of the emergence tolerance during antidepressant treatment for major depressive disorder (MDD). It is firstly unclear to what extent this phenotype reflects a pharmacological effect of an antidepressant, is driven by non-adherence, is a marker of latent bipolarity or another comorbidity, a marker of neuroprogression of the underlying disorder…

0301 basic medicineEmotional bluntingLoss of efficacyAntidepressantTreatment-resistanceSerotonergicloss of response03 medical and health sciences0302 clinical medicinetachyphylaxisMedicineRelapseswitch.Depression (differential diagnoses)treatment-resistancerelapsePharmacologyantidepressantwithdrawalbusiness.industryOperational definitionSwitchloss of efficacymedicine.diseaseComorbidity030104 developmental biologyWithdrawal030220 oncology & carcinogenesisMajor depressive disorderAntidepressantLoss of responsebusinessTachyphylaxiTolerancePsychosocialClinical psychologyPharmacological Research
researchProduct

The more the merrier? Scoring, statistics and animal welfare in experimental autoimmune encephalomyelitis.

2016

Experimental autoimmune encephalomyelitis (EAE) is a frequently used animal model for the investigation of autoimmune processes in the central nervous system. As such, EAE is useful for modelling certain aspects of multiple sclerosis, a human autoimmune disease that leads to demyelination and axonal destruction. It is an important tool for investigating pathobiology, identifying drug targets and testing drug candidates. Even though EAE is routinely used in many laboratories and is often part of the routine assessment of knockouts and transgenes, scoring of the disease course has not become standardized in the community, with at least 83 published scoring variants. Varying scales with diffe…

0301 basic medicineEncephalomyelitis Autoimmune Experimental3400 General Veterinary610 Medicine & healthAnimal WelfareDisease course03 medical and health sciences0302 clinical medicineAnimal modelAnimals LaboratorymedicineAnimalsStatistical analysis10239 Institute of Laboratory Animal SciencerefinementAutoimmune diseasescoring scalesGeneral VeterinaryAnimal Welfare (journal)business.industryEAEMultiple sclerosisExperimental autoimmune encephalomyelitismedicine.diseasehumane endpointsDisease Models Animal030104 developmental biologyResearch DesignAnimals Domestic570 Life sciences; biologyAnimal Science and Zoology1103 Animal Science and ZoologybusinessNeuroscience030217 neurology & neurosurgeryLaboratory animals
researchProduct

IL ‐1 signaling is critical for expansion but not generation of autoreactive GM ‐ CSF + Th17 cells

2016

Abstract Interleukin‐1 (IL‐1) is implicated in numerous pathologies, including multiple sclerosis and its animal model experimental autoimmune encephalomyelitis (EAE). However, the exact mechanism by which IL‐1 is involved in the generation of pathogenic T cells and in disease development remains largely unknown. We found that following EAE induction, pertussis toxin administration leads to IL‐1 receptor type 1 (IL‐1R1)‐dependent IL‐1β expression by myeloid cells in the draining lymph nodes. This myeloid‐derived IL‐1β did not vitally contribute to the generation and plasticity of Th17 cells, but rather promoted the expansion of a GM‐CSF + Th17 cell subset, thereby enhancing its encephalitog…

0301 basic medicineEncephalomyelitis Autoimmune ExperimentalBiologymedicine.disease_causePertussis toxinGeneral Biochemistry Genetics and Molecular BiologyAutoimmunityMice03 medical and health sciences0302 clinical medicineMediatormedicineAnimalsInducerMolecular BiologyCell ProliferationGeneral Immunology and MicrobiologyGeneral NeuroscienceMultiple sclerosisExperimental autoimmune encephalomyelitisGranulocyte-Macrophage Colony-Stimulating FactorArticlesmedicine.diseaseCell biology030104 developmental biologyPertussis ToxinT cell subsetImmunologyTh17 CellsLymphInterleukin-1030215 immunologyThe EMBO Journal
researchProduct